Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine ...
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and …
AUSTEDO XR® Medication for Tardive Dyskinesia (TD)
Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.
Deutetrabenazine Tablets Improve Tardive Dyskinesia Symptoms
Oct 22, 2025 · She added, “These data articulate patient experience and further validate clinical research showing how AUSTEDO or AUSTEDO XR can help people living with tardive dyskinesia …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Nov 7, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. …
Phase 4 Data Support Effectiveness of Deutetrabenazine in ...
Nov 26, 2025 · Teva Pharmaceuticals announced data from the ongoing real-world phase 4 study, coined IMPACT-TD Registry, evaluating the efficacy of deutetrabenazine (Austedo) tablets and its …
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are taken once …
Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia ...
Nov 12, 2025 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 inhibitor approved …
Teva Pharmaceuticals Reports Positive Real-World Data on ...
Nov 7, 2025 · Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of adults with …
What is the FDA-Approved Treatment for Tardive Dyskinesia?
Nov 26, 2025 · Learn about the FDA-approved treatment for tardive dyskinesia, specifically the VMAT2 inhibitors valbenazine (Ingrezza) and deutetrabenazine (Austedo).
Austedo: Regaining Control Over Uncontrolled Movements in ...
Austedo (aw-STED-oh) was approved in 2017 and is the first medicine approved to treat both tardive dyskinesia and chorea caused by Huntington’s disease.